iTeos Therapeutics’ (ITOS) “Outperform” Rating Reiterated at Wedbush

iTeos Therapeutics (NASDAQ:ITOS)‘s stock had its “outperform” rating reaffirmed by Wedbush in a report released on Wednesday,RTT News reports. They presently have a $25.00 price target on the stock. Wedbush’s price target indicates a potential upside of 244.35% from the stock’s current price.

Several other analysts have also issued reports on ITOS. Wells Fargo & Company cut their target price on shares of iTeos Therapeutics from $31.00 to $19.00 and set an “overweight” rating for the company in a research report on Thursday, December 19th. HC Wainwright restated a “buy” rating and issued a $21.00 price objective on shares of iTeos Therapeutics in a research note on Thursday, January 16th.

iTeos Therapeutics Stock Up 6.0 %

ITOS traded up $0.41 during mid-day trading on Wednesday, reaching $7.26. 463,605 shares of the company traded hands, compared to its average volume of 447,781. The stock has a market capitalization of $265.24 million, a P/E ratio of -2.30 and a beta of 1.38. The company’s fifty day moving average price is $7.54 and its 200-day moving average price is $9.57. iTeos Therapeutics has a 52-week low of $6.67 and a 52-week high of $18.75.

iTeos Therapeutics (NASDAQ:ITOS) last posted its earnings results on Wednesday, March 5th. The company reported ($1.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.14) by $0.13. As a group, sell-side analysts forecast that iTeos Therapeutics will post -3.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On iTeos Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Point72 DIFC Ltd bought a new stake in iTeos Therapeutics during the 3rd quarter valued at approximately $31,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in iTeos Therapeutics during the 4th quarter valued at approximately $42,000. Virtus ETF Advisers LLC raised its position in shares of iTeos Therapeutics by 58.2% during the fourth quarter. Virtus ETF Advisers LLC now owns 8,948 shares of the company’s stock valued at $69,000 after buying an additional 3,293 shares during the last quarter. Forefront Analytics LLC purchased a new position in shares of iTeos Therapeutics in the fourth quarter worth $85,000. Finally, Graham Capital Management L.P. bought a new position in shares of iTeos Therapeutics during the fourth quarter worth $85,000. Hedge funds and other institutional investors own 97.16% of the company’s stock.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.